Seqirus phase III trial of cell-based quadrivalent influenza vaccine in healthy children aged 6 to 47 months

Phase 3, randomised, single-blind trial of influenza vaccine surface antigen inactivated prepared in cell cultures in influenza (2 arms), sponsored by CSL Seqirus. Primary endpoint: First occurrence of RT-PCR confirmed influenza. Started Dec 2018; status: completed.